Responses
Clinical/translational cancer immunotherapy
Original research
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
Compose a Response to This Article
Other responses
No responses have been published for this article.
